equillium, inc., a clinical-stage biotechnology company, develops products for autoimmune and inflammatory, or immuno-inflammatory disorders with unmet medical need. its primary product candidate is itolizumab, a clinical-stage monoclonal antibody that targets the novel immune checkpoint receptor cd6, which is in phase 1b/2 clinical trials for the treatment of acute graft-versus-host disease; and phase 1 clinical trial for the treatment of asthma and lupus nephritis. the company was formerly known as attenuate biopharmaceuticals, inc. and changed its name to equillium, inc. in may 2017. equillium, inc. was founded in 2017 and is headquartered in la jolla, california.
Company profile
Ticker
EQ
Exchange
Website
CEO
Bruce Steel
Employees
Incorporated
Location
Fiscal year end
Industry (SIC)
SEC CIK
Corporate docs
Subsidiaries
Equillium AUS Pty Ltd. • Bioniz Therapeutics, Inc. ...
IRS number
821554746
EQ stock data
Latest filings (excl ownership)
ARS
2023 FY
Annual report to shareholders
11 Apr 24
DEFA14A
Additional proxy soliciting materials
11 Apr 24
DEF 14A
Definitive proxy
11 Apr 24
PRE 14A
Preliminary proxy
1 Apr 24
8-K
Other Events
1 Apr 24
S-8
Registration of securities for employees
25 Mar 24
10-K
2023 FY
Annual report
25 Mar 24
8-K
Equillium Reports on Fourth Quarter and Full Year 2023 Financial Results and Corporate and Clinical Highlights
25 Mar 24
8-K
Departure of Directors or Certain Officers
8 Mar 24
8-K
Results of Operations and Financial Condition
23 Feb 24
Latest ownership filings
Financial summary
Quarter (USD) | Sep 23 | Jun 23 | Mar 23 | Dec 22 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Annual (USD) | Dec 22 | Dec 21 | Dec 20 | Dec 19 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Cash burn rate (est.) | Burn method: Change in cash | Burn method: Operating income | Burn method: FCF (opex + capex) | Last Q | Avg 4Q | Last Q | Avg 4Q | Last Q | Avg 4Q |
---|---|---|---|---|---|---|
Cash on hand (at last report) | 34.38 mm | 34.38 mm | 34.38 mm | 34.38 mm | 34.38 mm | 34.38 mm |
Cash burn (monthly) | (no burn) | (no burn) | 1.21 mm | 712.42 k | 636.33 k | (no burn) |
Cash used (since last report) | n/a | n/a | 8.00 mm | 4.72 mm | 4.21 mm | n/a |
Cash remaining | n/a | n/a | 26.38 mm | 29.66 mm | 30.17 mm | n/a |
Runway (months of cash) | n/a | n/a | 21.8 | 41.6 | 47.4 | n/a |
Institutional ownership, Q3 2023
42.1% owned by funds/institutions
13F holders | Current |
---|---|
Total holders | 27 |
Opened positions | 4 |
Closed positions | 3 |
Increased positions | 4 |
Reduced positions | 6 |
13F shares | Current |
---|---|
Total value | 6.58 bn |
Total shares | 14.85 mm |
Total puts | 200.00 |
Total calls | 22.30 k |
Total put/call ratio | 0.0 |
Largest owners | Shares | Value |
---|---|---|
Decheng Capital Global Life Sciences Fund IV | 5.73 mm | $48.67 mm |
Decheng Capital Management III | 4.45 mm | $3.29 bn |
BEN Franklin Resources | 895.00 k | $662.30 mm |
JPM JPMorgan Chase & Co. | 873.61 k | $646.47 mm |
Vanguard | 836.93 k | $619.33 mm |
Cota Capital Management | 562.28 k | $416.09 mm |
Tang Capital Management | 400.00 k | $296.00 mm |
Renaissance Technologies | 293.29 k | $217.00 k |
Geode Capital Management | 172.39 k | $127.59 mm |
Bridgeway Capital Management | 125.50 k | $92.87 mm |
Recent insider trades
Date | Owner | Security | Transaction | Code | Indirect | 10b5-1 | $Price | #Shares | $Value | #Remaining |
---|---|---|---|---|---|---|---|---|---|---|
2 Jan 24 | Zedelmayer Christine | Employee Stock Option Common Stock | Grant | Acquire A | No | No | 0.73 | 175,000 | 127.75 k | 175,000 |
2 Jan 24 | Connelly Stephen | Employee Stock Option Common Stock | Grant | Acquire A | No | No | 0.73 | 175,000 | 127.75 k | 175,000 |
2 Jan 24 | Steel Bruce D. | Employee Stock Option Common Stock | Grant | Acquire A | No | No | 0.73 | 410,000 | 299.30 k | 410,000 |
2 Jan 24 | Bradbury Daniel | Employee Stock Option Common Stock | Grant | Acquire A | No | No | 0.73 | 50,000 | 36.50 k | 50,000 |
8 Dec 23 | Zedelmayer Christine | Common Stock | Grant | Acquire A | No | No | 0.58 | 8,804 | 5.11 k | 135,246 |
9 Jun 23 | Zedelmayer Christine | Common Stock | Grant | Acquire A | No | No | 0.56 | 15,000 | 8.40 k | 126,442 |
News
HC Wainwright & Co. Maintains Buy on Equillium, Raises Price Target to $5
2 Apr 24
Why Westport Fuel Systems Shares Are Trading Lower By Around 10%? Here Are Other Stocks Moving In Tuesday's Mid-Day Session
26 Mar 24
12 Health Care Stocks Moving In Tuesday's Intraday Session
26 Mar 24
Equillium: Q4 Earnings Insights
25 Mar 24
Equillium Q4 2023 GAAP EPS $(0.07) Beats $(0.17) Estimate, Sales $9.200M Beat $6.425M Estimate
25 Mar 24
Press releases
Thinking about buying stock in Braze, Velo3D, InterCure, Equillium, or Bioatla?
28 Mar 24
Thinking about trading options or stock in Advanced Micro Devices, Equillium, Macy's, Alphabet, or Phillips 66?
27 Mar 24
Thinking about buying stock in Equillium, Kuke Music, Altamira Therapeutics, MoneyHero, or Enerplus?
26 Mar 24
Equillium to Present at the H.C. Wainwright Autoimmune & Inflammatory Disease Conference and the LD Micro Invitational Conference
22 Mar 24